Results 71 to 80 of about 65,035 (206)
MicrobiologyOpen, Volume 15, Issue 3, June 2026.Griffithsin, Brevinin‐2, and CCL20 were identified as potent MERS‐CoV fusion inhibitor candidates targeting the HR2 domain through integrated molecular docking, MD simulations, and MM/PBSA analyses. These peptides demonstrated superior binding stability and favorable safety profiles compared to the standard inhibitor, supporting their potential as ...
Nasser Alotaiq +2 more
wiley +1 more source
SYNERGY IN MIXED RIBAVERIN-INTERFERON AQUEOS SOLUTIONS
Сеченовский вестник, 2017 Spectrophotometric method of ribavirin determination in aqueous solutions was improved. Feasibility of ribavirin determination in the presence of protein was confirmed.
K. Kienskaya +8 more
doaj
Ribavirin Induces Polyamine Depletion via Nucleotide Depletion to Limit Virus Replication
Cell Reports, 2019 Summary: Common antivirals include nucleoside or nucleotide analogs with base prodrugs. The antiviral ribavirin, a US Food and Drug Administration (FDA)-approved nucleoside antimetabolite, halts guanine production, mutagenizes viral genomes, and ...
Patrick M. Tate +2 more
doaj +1 more source
Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C. [PDF]
PLoS ONE, 2012 Ribavirin improves outcomes of therapy in chronic hepatitis C but its mode of action has still remained unclear. Since ribavirin has been proposed to modulate the host's T cell responses, we studied its direct effects on CD4(+) T cell clones with diverse
Bettina Langhans +6 more
doaj +1 more source
Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C [PDF]
, 2015 Hepatitis C virus (HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma (HCC), one of the most common fatal cancers worldwide - fourth for ...
Fassina, Giorgio +3 more
core +1 more source
A Framework for Emergency Department–Integrated Hepatitis C Test‐and‐Treat in the United States
Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.ABSTRACT Despite the availability of curative, direct‐acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align
Saeed S. Graham
wiley +1 more source
Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.ABSTRACT Achieving hepatitis C virus (HCV) elimination requires innovative paradigms that overcome barriers to treatment, such as requiring pre‐treatment elastography or phlebotomy‐based fibrosis assessment. To identify patients at low risk of advanced fibrosis or decompensated cirrhosis within our HCV treatment programme, we developed and ...
Hunter Spencer +4 more
wiley +1 more source
PLoS ONE, 2019 Epithelial ovarian cancers are insidious pathologies that give a poor prognosis due to their late discovery and the increasing emergence of chemoresistance. Development of small pharmacological anticancer molecules remains a major challenge.
Anaïs Wambecke +8 more
doaj +1 more source
Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production. [PDF]
PLoS ONE, 2015 Ribavirin is used as a component of combination therapies for the treatment of chronic hepatitis C virus (HCV) infection together with pegylated interferon and/or direct-acting antiviral drugs. Its mechanism of action, however, is not clear.
Yang Wang +7 more
doaj +1 more source